Literature DB >> 20635884

Immunotherapy and neuroimmunology in Alzheimer's disease: a perspective from the blood-brain barrier.

William A Banks.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20635884     DOI： 10.2217/imt.09.72

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  4 in total

1.  Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease.

Authors:  Giuseppina Cantarella; Giulia Di Benedetto; Daniela Puzzo; Lucia Privitera; Carla Loreto; Salvatore Saccone; Salvatore Giunta; Agostino Palmeri; Renato Bernardini
Journal:  Brain       Date:  2014-12-02       Impact factor: 13.501

2.  Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer's Disease.

Authors:  Teresa Musumeci; Giulia Di Benedetto; Claudia Carbone; Angela Bonaccorso; Giovanni Amato; Maria Josè Lo Faro; Chiara Burgaletto; Giovanni Puglisi; Renato Bernardini; Giuseppina Cantarella
Journal:  Biomedicines       Date:  2022-04-23

3.  Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.

Authors:  Mei Ji; Xi-Xiu Xie; Dong-Qun Liu; Xiao-Lin Yu; Yue Zhang; Ling-Xiao Zhang; Shao-Wei Wang; Ya-Ru Huang; Rui-Tian Liu
Journal:  Alzheimers Res Ther       Date:  2018-06-19       Impact factor: 6.982

4.  Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy.

Authors:  Clara Theunis; Natalia Crespo-Biel; Valérie Gafner; Maria Pihlgren; María Pilar López-Deber; Pedro Reis; David T Hickman; Oskar Adolfsson; Nathalie Chuard; Dorin Mlaki Ndao; Peter Borghgraef; Herman Devijver; Fred Van Leuven; Andrea Pfeifer; Andreas Muhs
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.